Stay updated on Copanlisib and Nivolumab in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Copanlisib and Nivolumab in Lymphoma Clinical Trial page.

Latest updates to the Copanlisib and Nivolumab in Lymphoma Clinical Trial page
- Check6 days agoChange DetectedThe page's revision label has been updated from v3.5.3 to v3.5.4, indicating a new page snapshot. This reflects a minor update to the page's version/history.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a site build update rather than a change to the study details.SummaryDifference0.0%

- Check34 days agoChange DetectedRevision: v3.5.2 has been added, replacing the previous Revision: v3.5.0.SummaryDifference0.0%

- Check48 days agoChange DetectedAdded the condition term Malignant lymphoma, large B-cell, diffuse to the study's conditions. Included a new Resources entry linking to the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision: v3.5.0. No obvious changes to the study details or user-facing content are visible compared to the previous version.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Copanlisib and Nivolumab in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Copanlisib and Nivolumab in Lymphoma Clinical Trial page.